(2025) reported that as a key enzyme in glycolysis/glycogen metabolism (catalyzing G1P/G6P ↔ G1,6BP), PGM2L1 may affect CCA progression by promoting metabolic reprogramming and modulating the immune microenvironment (201). This evidence concerns the gene PGM2L1 and cholangiocarcinoma.